

Genetics and Outcomes in Colorectal Cancer Disparities

Florida Society of Clinical Oncology

November 12, 2021

- John M. Carethers, M.D., M.A.C.P
- *C. Richard Boland Distinguished University Professor*
 - John G. Searle Professor of Internal Medicine




Epidemiology of CRC Disparities

Trends in SEER Age-adjusted CRC Incidence and Mortality


A

Colon and Rectum Cancer
Recent Trends in SEER Age-Adjusted Incidence Rates, 2000-2017
By Race/Ethnicity, Both Sexes, All Ages, All Stages, Delay-adjusted Rates



B

Colon and Rectum Cancer
Recent Trends in U.S. Age-Adjusted Mortality Rates, 2000-2018
By Race/Ethnicity, Both Sexes, All Ages



Created by <https://seer.cancer.gov/explorer> on Sun Nov 29 2020.
SEER 21 areas [<http://seer.cancer.gov/registries/terms.html>] (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
The Annual Percent Change (APC) estimates were calculated from the underlying rates using the Joinpoint Trend Analysis Software [<http://surveillance.cancer.gov/joinpoint>], Version 4.8, April 2020, National Cancer Institute.
The APC's direction is "rising" when the entire 95% confidence interval (C.I.) is above 0, "falling" when the entire 95% C.I. is lower than 0, otherwise, the trend is considered stable.
Rates for American Indians/Alaska Natives only include cases that are in a Purchased/Referred Care Delivery Area (PRCDA). See SEER Race Recode Documentation for American Indian/Alaskan Native Statistics [http://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/#ai-an].
Hispanics and Non-Hispanics are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics and Non-Hispanics are based on the NAACCR Hispanic Latino Identification Algorithm (NHIA) and exclude cases from the Alaska Native Registry. See SEER Race Recode Documentation for Spanish-Hispanic-Latino Ethnicity [http://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/#hispanic].
See SEER*Explorer Cancer Site Definitions [<https://seer.cancer.gov/explorer/cancer-sites.html>] for details about the coding used for SEER Incidence data.

Created by <https://seer.cancer.gov/explorer> on Sun Nov 29 2020.
US Mortality Files, National Center for Health Statistics, CDC.
Rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).
The Annual Percent Change (APC) estimates were calculated from the underlying rates using the Joinpoint Trend Analysis Software [<http://surveillance.cancer.gov/joinpoint>], Version 4.8, April 2020, National Cancer Institute.
The APC's direction is "rising" when the entire 95% confidence interval (C.I.) is above 0, "falling" when the entire 95% C.I. is lower than 0, otherwise, the trend is considered stable.
Rates for American Indians/Alaska Natives only include cases that are in a Purchased/Referred Care Delivery Area (PRCDA). See SEER Race Recode Documentation for American Indian/Alaskan Native Statistics [http://seer.cancer.gov/seerstat/variables/seer/race_ethnicity/#ai-an].
Hispanics and Non-Hispanics are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. See the Policy for Calculating Hispanic Mortality [http://seer.cancer.gov/seerstat/variables/mort/origin_recode_1990+/index.html].
Cancer sites are defined using the SEER Cause of Death Recode 1969+ (04/16/2012) [https://seer.cancer.gov/code/recode/1969+_d04162012/index.html].

Global Cancer 5-Year Survival Rates

Table 5. Five-year Net Survival Rates* (%) among Adults 15 Years of Age and Older in Select Countries by Cancer Site, 2010-2014

	Esophagus	Stomach	Colon	Rectum	Liver	Lung	Female Breast	Cervix	Prostate
Asia									
Chinese registries	30	36	58	57	14	20	83	68	69
Indian registries	4	9	39	30	6†	4	66	59	44
Israel	26	32	72	68	19†	27	88	67	96
Kuwait	25†	22	59	58	19	13	75	57	84
Malaysia (Penang)	14†	30	56	58	10†	10	65†	57†	88
South Korea	31	69	72	71	27	25	87	77	90
Thai registries	7	13	47	44	7	9	69†	54†	68
Turkish registries	19	25	55	53	16	15	82	61	84
Northern America									
Canada	16	30	67	67	19	21	88	67	94
US registries	20	33	65	64	17	21	90	63	97
Central and Southern America									
Brazilian registries	10†	21†	48†	42†	11†	9	75†	60	92
Chilean registries	9	17	44†	33†	4†	5†	76†	57†	82†
Colombian registries	11†	17†	35†	38†	5†	9†	72†	49†	80†
Costa Rica	21†	41	60	54	24†	20†	87	78†	93
Europe									
Austria	19	35	64	64	15†	20	85	64	90
Belgium	24	38	68	67	21	18	86	65	94
Czech Republic	10	21	56	52	7	11	81	61	85
Denmark	14	20	62	65	8	17	86	70	86
Estonia	5	29	58	55	4	17	77	67	86
German registries	21	34	65	62	13	18	86	65	92
Italian registries	14	31	64	61	20	16	86	67	90
Polish registries	9	21	53	48	11	14	77	55	78
Slovenia	9	29	62	60	7	15	84	66	85
Spanish registries	13	28	63	60	17	14	85	65	90
UK registries	16	21	60	63	13	13	86	64	89
Oceania									
Australian registries	24	32	71	71	19	19	90	66	95
New Zealand	15	26	64	66	19	15	88	67	90

- CRC survival (all stages) ranges from 30% (India) to 71% (South Korea, Australia), depending on country
- No real data from African countries in report

*Survival rates are age-standardized. †Data are subject to limitations. Please see source.


Source: Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *Lancet*. Jan 30 2018. doi: 10.1016/S0140-6736(17)33326-3.

©2018, American Cancer Society, Inc., Surveillance Research


American Cancer Society. *Global Cancer Facts & Figures 4th Edition*. Atlanta: American Cancer Society; 2018.

Root Causes of CRC Disparities

Risk Factors for Colorectal Cancer



Connections and Consequences Initiated by Socioeconomic Disparities for CRC Risk



Unique Biological, Genetic,
Immunologic and
Screening Changes for
CRC Disparities



Summary of Differences in Black CRCs and Patients

Biological differences for Black American CRC risk as compared to White CRC risk
Increased number of adenomas >9mm
Increased proximal number of adenomas >9mm
Earlier onset of sporadic CRC
Increased proximal CRCs
Increase sulfidogenic bacteria in colon
Increased pro-inflammatory <i>Fusobacterium</i> and <i>Enterobacter</i> species in colon
Genetic differences for Black American CRC risk
Decreased frequency of MSI-H CRCs
Increased frequency of inflammation-associated microsatellite alterations/EMAST
Unique somatic <i>FLCN</i> , <i>EPHA6</i> , and <i>HTR1F</i> mutation
Increased frequency of KRAS mutation
Immunologic differences for Black American CRC risk
Decreased high numbers of CD8 ⁺ T lymphocytes within CRC
Decreased numbers of granzyme B ⁺ T lymphocytes withing CRC
Screening and surveillance differences for Black American CRC risk
Lower frequency of population CRC screening uptake
Lower frequency of colonoscopy screening uptake
Lower frequency of follow-up after positive non-invasive CRC screening test


Carethers JM. *Adv Cancer Res* 2021;**151**:197-229.

Screening Utilization Contributions to CRC Disparities and Mitigation Strategies

General Guidelines for Screening and Surveillance for Colorectal Cancer




CRC Screening and CRC Incidence Trends



CRC Screening Rates in 2020

- 65% Whites
- 62% Blacks




Siegel RL et al. *CA Cancer J Clin* 2020;**70**:1-20
 Siegel R et al. *CA Cancer J Clin* 2021;**71**:7-33

Strategies to Reduce Disparity of CRC in African Americans



Strategy	Advantages	Disadvantages
Patient education	<ul style="list-style-type: none"> • Direct to consumer • Addresses patient-level barriers (e.g., fear, mistrust, etc) 	<ul style="list-style-type: none"> • Cost • Ability to effectively reach certain target populations (i.e. those with low health literacy)
Physician education	<ul style="list-style-type: none"> • AAs report lower rates of physician recommendation for screening 	<ul style="list-style-type: none"> • No data on effectiveness • Cost • Broad target population (e.g., gastroenterologists, primary care, etc)
Patient navigation	<ul style="list-style-type: none"> • Evidence for benefit in increasing colonoscopy screening for AAs • Cost effective 	<ul style="list-style-type: none"> • Cost and insurance coverage • Training • Implementation
Increased screening by any method at age 50	<ul style="list-style-type: none"> • Low screening rates among AAs • Most CRCs develop after age 50 • AAs might prefer non-colonoscopy screening 	<ul style="list-style-type: none"> • Confusion about preferred modality • AAs have increased risk of right-sided neoplasia
Modify age for screening	<ul style="list-style-type: none"> • Reduces burden of early-onset disease • Raises awareness of increased risk • Life years gained by earlier screening 	<ul style="list-style-type: none"> • Increased confusion in guidelines • No prospective study of effectiveness • Most CRCs develop after age 50

Delaware Cancer Consortium

AA CRC STAGE AT DIAGNOSIS



- Funded through state
- Colonoscopy preferred
- 10,000 Navigations
- AA: 47.8% in 2001 to **73.5%** in 2009
- White: 58.0% in 2001 to **74.7%** in 2009



Grubbs SS *et al.* *J Clin Oncol* 2013;**31**:1928-1930

Similarities Between Cancer Disparities and COVID-19

CANCER

- Series of genetic diseases
 - Germline predisposition
 - Somatic DNA mutations
- Local environmental influences
 - Inflammation
 - Microbiome
- Onset over months to years
- Asymptomatic screening is part of routine health care

common to both

- Socioeconomic disparity
 - Level of Income and employment
 - Housing and location
 - Level of medical insurance
- Level of education
- Lifestyle factors and co-morbidities
 - Tobacco
 - Alcohol
 - Diet and obesity
- Reduced access to medical care
 - Delayed prevention or care
- Fear of clinical trial participation
- Higher risk of acquiring disease
- Higher risk of death from disease
- Survivorship medical and socioeconomic issues

COVID-19

- Single infectious disease
- Local environmental influences
 - ACE2 receptor
- Onset over hours to days
- Symptomatic screening
 - With widespread testing, can move to asymptomatic screening

COVID-19 Effects on Race/Ethnicity


Deaths by Race/Ethnicity:



Download


Data from 190,759 deaths. Race/Ethnicity was available for 150,803 (79%) deaths.

All Age Groups



Hispanic and black Americans have been hardest hit in COVID-19 wage, job losses; most do not have rainy day funds

% saying they or someone in their household has lost a job or taken a pay cut due to the corona virus outbreak



% who said in April they do not have rainy day funds to cover expenses for three months in case of emergency






Note: Whites and blacks include those who report being only one race and are non-Hispanic. Hispanics are of any race. Share of respondents who didn't provide an answer not shown. Source: Surveys of U.S. adults conducted March 19-24 and April 7-12, 2020.

PEW RESEARCH CENTER

<https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>


<https://www.pewresearch.org/fact-tank/2020/05/05/financial-and-health-impacts-of-covid-19-vary-widely-by-race-and-ethnicity>

COVID-19 Effect of Cancer Care



London JW et al. *JCO Clin Cancer Inform* 2020;4:657-665.

Cancer Screening in the COVID-19 Era



	Scenario	Factors affecting scenario	Relative # cancer deaths from baseline trajectory
A	rapid return to screening trajectory within 6-12 months	<ul style="list-style-type: none"> no further COVID-19 shutdowns of clinical capacity unrestricted screening capacity 	~1000 annually
B	delayed return to trajectory over 1-3 years	<ul style="list-style-type: none"> restricted/delayed screening capacity due to COVID-19 testing (preventing some screening services) and social distancing 	1000-5000 annually
C	prolonged return to trajectory over several years	<ul style="list-style-type: none"> prolonged screening capacity restraints due to large backlogs of delayed screening potential public and individual awareness for screening wanes exacerbation of fears for clinic settings due to ongoing pandemic 	≥5000-10,000 annually

Carethers JM, et al. *Cancer Prev Res* 2020;**13**:893-896.
 Sharpless NE. *Science* 2020;**368**:1290.

COVID-19 and Disparities

- Potential exacerbation of disparities with:
 - Disruption and access for acute medical care
 - Long term consequences with disruption of preventive care
 - Food insecurity
- Additional issues
 - Use of video vs phone for telehealth in COVID-19 / post-COVID-19 era
 - Worsening enrollment and outreach for underrepresented minorities to participate in clinical trials

Issues and Messaging

- Don't delay preventive healthcare just because of COVID-19
 - Exceptions are if you are positive, and it is not an emergency
 - With excessive delay, will cost some lives
- At-Home CRC screening
 - Lesser in cost
 - Need to mail to home
 - Some still have difficulty in completing test correctly
 - May require navigation
 - Provider / Health System must follow up on negative and positive tests
 - Positive tests need colonoscopy (may require additional navigation)
 - Some patients may still be hesitant due to COVID-19
 - Loopholes for screening vs diagnostic colonoscopy and out-of-pocket costs

Colon Cancer is Preventable – Let's Get Screened!



Chadwick Boseman (2016)



Ruth Bader Ginsburg (1999)



Sharon Osbourne (2003)



Elizabeth Montgomery (1995)



Audrey Hepburn (1993)
Ronald Reagan (1985)



Eartha Kitt (2008)



Vince Lombardi (1970)



Clarence Williams III (2021)

Thank You!